Novartis said it resumed the production and delivery of radioligand therapy medicines after fixing the issues that had led to a temporary suspension of production last month.
"The company has remediated the issues that led to the temporary, voluntary suspension of production in May," the Swiss drugmaker said in a statement, adding these issues did not affect patient safety.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.